Clinical outcomes in Black patients with EGFR-mutated NSCLC treated with osimertinib

被引：0
|
作者：
Belani, Neel
Rizwan, Farsha
Hasler, Jill
Bauman, Jessica
Mitchell, Khadijah
Borghaei, Hossein
Bodor, Joseph N.
机构：
来源：
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | 2024年 / 33卷 / 09期
关键词：
D O I：
10.1158/1538-7755.DISP24-A087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A087
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Comprehensive assessment of pretreatment sarcopenia impacts on patients with EGFR-mutated NSCLC treated with afatinib
    Wu, Chen-Te
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Wu, Chiao-En
    THORACIC CANCER, 2023, 14 (25) : 2548 - 2557
  • [42] Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
    Hidetoshi Hayashi
    Makoto Nishio
    Michiko Takahashi
    Hiroaki Tsuchiya
    Mami Kasahara-Kiritani
    Advances in Therapy, 2023, 40 : 4545 - 4560
  • [43] Disease Monitoring of EGFR-mutated NSCLC Patients Treated with TKIs via EGFR Status in Circulating ctDNA
    Li, Y.
    Xu, Z.
    Wang, S.
    Zhu, Y.
    Ma, D.
    Mu, Y.
    Ying, J.
    Xing, P.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S445 - S445
  • [44] EGFR-Mutated NSCLC: Clinical Practice Assessment and Gap Analysis
    Herrmann, Tara
    Hamarstrom, Elaine
    Ramalingam, Suresh
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1218 - S1219
  • [45] Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
    Aredo, J.
    Wakelee, H. A.
    Neal, J.
    Padda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S619 - S619
  • [46] Real-World-Data on First-Line Therapy with Osimertinib in Patients with advanced EGFR-mutated NSCLC
    Griesinger, F.
    Nieva, J.
    Kim, Y.
    Cohen, A.
    Horvat, P.
    Lu, S.
    Taylor, A.
    Yu, N.
    Shenolikar, R.
    Shaw, S.
    PNEUMOLOGIE, 2021, 75 : S11 - S11
  • [47] Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
    Planchard, D.
    Toffart, A. C.
    Flandin, A-C. Madroszyk
    Wislez, M.
    Martinez, S.
    Monnet, I.
    Hiret, S.
    Gounant, V.
    Metivier, A-C.
    Domblides, C.
    Giroux-Leprieur, E.
    Huchot, E.
    Tomasini, P.
    Mascaux, C.
    Carmier, D.
    Langlais, A.
    Morin, F.
    Westeel, V.
    Cortot, A.
    ANNALS OF ONCOLOGY, 2023, 34
  • [48] Correlating osimertinib and erlotinib pharmacokinetics with efficacy and toxicity in EGFR-mutated NSCLC patients (START-TKI study)
    Veerman, G. D. M.
    Steendam, C. M. J.
    Koolen, S. L.
    Oomen-de Hoop, E.
    Dingemans, A-M. C.
    Aerts, J. G. J. V.
    Mathijssen, R. H.
    ANNALS OF ONCOLOGY, 2020, 31 : S861 - S862
  • [49] Resistance Mechanisms to Osimertinib in Advanced EGFR-mutated NSCLC: A Single Institution Prospective Cohort Study
    Liao, B. -C.
    Yang, C. -Y.
    Tsai, T. -H.
    Liao, W. -Y.
    Chen, K. -Y.
    Ho, C. -C.
    Shih, J. -Y.
    Yu, C. -J.
    Yang, J. C. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S463 - S463
  • [50] Cumulative Smoking Dose Affects the Clinical Outcomes of EGFR-Mutated Lung Adenocarcinoma Patients Treated with EGFR-TKIs
    Kim, I. A.
    Kim, H. J.
    Lee, J. S.
    Lee, K. Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2138 - S2138
12345